Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Phase 3 – large-scale trial before approval
Conditions:
Hemophilia A
Hemophilia B
Sponsor: Pfizer
trial.available_in:
БГ
Overview
A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.
Who can participate
Inclusion Criteria:
-Only participants who received investigational giroctocogene fitelparvovec or fidanacogene eleparvovec and were enrolled in a Pfizer-sponsored study (C0371002, C0371003, C0371005, C3731001, C3731003) are eligible.
Exclusion Criteria:
-None
Locations
4
Australia (1)
Royal Prince Alfred Hospital
Camperdown , New South Wales
Taiwan (1)
National Taiwan University Hospital
Taipei
NOT_YET_RECRUITING
Turkey (1)
Ege Universitesi Hastanesi
Izmir , İ̇zmir
United States (1)
The Regents of the University of California||UC Davis Health
БГ